This compound screen is of potential interest in the context of different diseases where C/EBPδ plays an important role, and the compounds that inhibit C/EBPδ activity may hold promise in lung adenocarcinoma, glioma and urothelial bladder cancer in which C/EBPδ is overexpressed and associates with poor survival [4, 5, 6]. This evidence concerns the gene CEBPD and bladder transitional cell carcinoma.